TREATMENT OF THE METABOLIC-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH  METABOLIC SYNDROME

Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/303

Full metadata record

DC Field	Value	Language
dc.contributor.author	SOBIROVA G.N., SAIDRASULOVA G.B., KARIMOV M.M.	-
dc.date.accessioned	2024-12-12T20:50:12Z	-
dc.date.available	2024-12-12T20:50:12Z	-
dc.date.issued	2024	-
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/303	-
dc.description.abstract	The study was conducted at Tashkent medical academy between 2022-2024. The study participated 165 patients with metabolic syndrome with signs of MAFLD also. Patients included to research with age between 45 and 75 years old. All participants were subject to demographic data, clinical, functional and biochemical markers	en_US
dc.language.iso	other	en_US
dc.publisher	"Ichki kasalliklarining dolzarb muammolari” mavzusida Xalqaro terapevtlar forumi	en_US
dc.subject	Aim. To evaluate the effect of supplementation with ademetionine for 3 months on lipidic and biochemical parameters in patients with metabolic syndrome and at risk of MAFLD	en_US
dc.title	TREATMENT OF THE METABOLIC-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME	en_US
dc.type	Thesis	en_US
Appears in Collections:	Articles

Files in This Item:

File	Description	Size	Format
17 Terapiya_N3_2024_ (1).pdf		410.36 kB	Adobe PDF	View/Open

DSpace JSPUI